Heterogeneity in refractory acute myeloid leukemia
Abstract
Acute myeloid leukemia (AML) is the name given to a diverse set of highly fatal blood cancers. The typical initial treatment is combination cytotoxic chemotherapy with at least two drugs: 7 days of cytarabine with 3 days of an anthracycline. As treatment at initial diagnosis is often given emergently, there is a great need for pretreatment markers capable of identifying patients for whom standard treatment is likely to be suboptimal. This work uses RNA-sequencing analysis of a diverse cohort of highly annotated AML patient samples to demonstrate heterogeneity among those patients not responding to standard chemotherapy, then uses this information both to develop a prognostic classifier for survival and to suggest potentially superior therapeutic approaches for those at highest risk.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 07, 2019
- Source ID
- 10.1073/pnas.1902375116
Entities
People
- Christin B DeStefano
- Christopher S Hourigan
- Gege Gui
- Justin Lack
- Michael M. Gottesman
- Sachi Horibata
Organizations
- National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- Uniformed Services University of the Health Sciences